This approval allows the company to enter the market with a generic equivalent of Uptravi® for injection, which is originally produced by Actelion Pharmaceuticals US, Inc. Notably, the manufacturing of this generic product will take place at Lupin's facility located in Nagpur, India.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment